Fluoroquinolone Prophylaxis Reduces Intensive Care Unit Admission and Clostridioides difficile Rates in Acute Myeloid Leukemia Induction Chemotherapy [0.03%]
氟喹诺酮类药物预防可降低急性髓系白血病诱导化疗患者的重症监护病房入住率和难辨梭状芽孢杆菌感染率
Charles J Weeks,Sujith Abbagoni,Faizan Boghani et al.
Charles J Weeks et al.
Background: Patients with acute myeloid leukemia (AML) undergoing induction chemotherapy are at high-risk of bloodstream infections, including central line-associated bloodstream infections (CLABSI) or mucosal barrier inj...
Unheard Voices: Unmet Psychosocial Needs of Carers of Myeloma-A Service Evaluation Exploring Patient and Carer Perceived Benefits of Attending a Myeloma Support Group [0.03%]
未被倾听的声音:多发性骨髓瘤患者的照顾者的心理社会需求未得到满足——一项关于患者和护理人员参加多发性骨髓瘤支持小组的获益感知的服务评价研究
Kerrie Sweeney,Joseph Bolger,Aaron Niblock
Kerrie Sweeney
High miR-202-5p Expression at Initial Diagnosis is Associated With Tyrosine Kinase Inhibitor Resistance In Chronic Myeloid Leukemia-A Result From a Nested Case-Control Study [0.03%]
初诊时高水平的miR-202-5p与慢性髓性白血病对酪氨酸激酶抑制剂的耐药相关性——巢式病例对照研究结果
Zi-Yuan Nie,Jia Wang,Zi-Yu Zhao et al.
Zi-Yuan Nie et al.
Background: Tyrosine kinase inhibitor (TKI) resistance remains a critical challenge in chronic myeloid leukemia (CML). While mechanistic studies implicate miR-202-5p in resistance, its clinical relevance as a biomarker at...
Durable Response to Glofitamab in HIV-Positive Refractory Burkitt Lymphoma: Case Report and Discussion [0.03%]
HIV阳性难治性伯基特淋巴瘤对Glofitamab的 durable response:案例报告和讨论
Bozzotto Elisa,Magnes Theresa,Kiem Dominik et al.
Bozzotto Elisa et al.
Background: Refractory Burkitt lymphoma (BL) has a dismal prognosis after failure of frontline therapy. New treatment options are urgently needed. Methods...
Accelerated Chronic Lymphocytic Leukaemia Complicated by Bilateral Pathological Humeral Fractures [0.03%]
慢性淋巴细胞性白血病合并双侧病理肱骨骨折病例报告
Mariyum Khawar,Varvara Bashkirova,Vidhya Manohar et al.
Mariyum Khawar et al.
Leukemic Regression After G-CSF Withdrawal in Severe Congenital Neutropenia [0.03%]
粒细胞集落刺激因子停用后先天性中性粒细胞减少症患者的白血病退行性改变
Agnese Roveta,Irene Trambusti,Marco Tellini et al.
Agnese Roveta et al.
Rod-Like Cytoplasmic Inclusions in the Peripheral Blood Smear of a Patient with Chronic Lymphocytic Leukemia [0.03%]
慢性淋巴细胞白血病患者外周血涂片中的杆状胞质包涵体
Abhishek Prasad,Tran B Nguyen,Luis F Carrillo
Abhishek Prasad
Teclistamab in Elderly Patients With Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis of the French RetrosTECtive Cohort [0.03%]
Teclistamab治疗复发/难治多发性骨髓瘤老年患者:法国RetrosTECtive队列亚组分析
A Coste,S Godet,S Manier et al.
A Coste et al.
Introduction: Real-world data on teclistamab in relapsed or refractory multiple myeloma (R/R MM), particularly in elderly patients, remain limited. Method...
Venous Thromboembolism in Aggressive B-Cell Lymphoma Patients Treated with CD19 CAR-T Therapy: Single-Institution Study [0.03%]
CD19 CAR-T治疗的侵袭性B细胞淋巴瘤患者的静脉血栓栓塞:单中心研究
Neha Venkatesh,Kevin Milligan,Julia Parrish et al.
Neha Venkatesh et al.
Background: Large B-cell lymphomas (LBCLs) are a common subtype of non-Hodgkin lymphomas. CD19 chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized LBCL treatment, with high remission rates but also signifi...
A Pilot Project to Evaluate the Benefit of Additional Support in Haematopoietic Cell Transplant (HCT) Research Data Management on Behalf of Anthony Nolan and BSBMTCT [0.03%]
一项评估在造血细胞移植(HCT)研究数据管理中增加支持益处的试点项目 代表Anthony Nolan和BSBMTCT开展的研究
Shelley Hewerdine,Greg Judge,Julia Lee et al.
Shelley Hewerdine et al.
Background: The participation of transplant centres in research studies that request detailed follow-up data on included patients can be challenging due to the amount of time centre Data Managers have to complete addition...